Annovis Bio (FRA:07X) ROCE %: -696.82% (As of Mar. 2026)


FRA:07X Annovis Bio Inc FRA:07X
32 GF Score
Price €1.48
! 1 Warning Sign
View Full Analysis

What is Annovis Bio ROCE %?

Annovis Bio FRA:07X -2.64% 32 ROCE % is -696.82% as of Mar. 2026. GuruFocus rates FRA:07X with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Annovis Bio's annualized ROCE % for the quarter that ended in Mar. 2026 was -696.82%.

Annovis Bio  (FRA:07X) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Annovis Bio ROCE % Related Terms

Annovis Bio ROCE % Historical Data

* Premium members only.

The historical data trend for Annovis Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio ROCE % Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -56.31 -72.85 -256.71 -339.24 -207.08

Annovis Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -145.26 -112.73 -183.40 -251.52 -696.82
FRA:07X
32GF Score
Annovis Bio Inc FRA:07X
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio ROCE % Calculation

Annovis Bio's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-25.36/( ( (13.299 - 3.706) + (18.004 - 3.104) )/ 2 )
=-25.36/( (9.593+14.9)/ 2 )
=-25.36/12.2465
=-207.08 %

Annovis Bio's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-62.32/( ( (18.004 - 3.104) + (14.051 - 11.064) )/ 2 )
=-62.32/( ( 14.9 + 2.987 )/ 2 )
=-62.32/8.9435
=-696.82 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -696.82% mean?
Annovis Bio (FRA:07X) has a ROCE % of -696.82% as of Mar. 2026.
Is Annovis Bio's ROCE % too high?
Annovis Bio's current ROCE % is -696.82%. Overall, Annovis Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's ROCE % compare to CSBR and HYFT?
Annovis Bio's ROCE % of -696.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Annovis Bio's current ROCE % is -696.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current ROCE % of -696.82%. The current ROCE % is -696.82%. Annovis Bio's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current ROCE % is -696.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
32GF Score

Get the complete analysis for FRA:07X

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price